Does the media favor CORT or SUPN?

In the previous week, Corcept Therapeutics had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Corcept Therapeutics and 2 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 1.49 beat Supernus Pharmaceuticals' score of 0.94 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRGO or SUPN?

In the previous week, Perrigo had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 11 mentions for Perrigo and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Perrigo's score of -0.20 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SUPN or PCRX?

In the previous week, Pacira BioSciences had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Pacira BioSciences and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Pacira BioSciences' score of 0.75 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SUPN or OMER?

In the previous week, Omeros had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Omeros and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Omeros' score of 0.31 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Supernus Pharmaceuticals (SUPN) Competitors

$44.41 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

Should you buy Supernus Pharmaceuticals stock or one of its competitors? MarketBeat compares Supernus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Corcept Therapeutics had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Corcept Therapeutics and 2 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 1.49 beat Supernus Pharmaceuticals' score of 0.94 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	11.69	$99.65M	$0.35	236.89
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A

Corcept Therapeutics currently has a consensus target price of $88.83, suggesting a potential upside of 7.14%. Supernus Pharmaceuticals has a consensus target price of $62.17, suggesting a potential upside of 39.98%. Given Supernus Pharmaceuticals' higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Nektar Therapeutics currently has a consensus price target of $149.63, indicating a potential upside of 151.98%. Supernus Pharmaceuticals has a consensus price target of $62.17, indicating a potential upside of 39.98%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 2 mentions for Supernus Pharmaceuticals and 1 mentions for Nektar Therapeutics. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Nektar Therapeutics' score of 0.82 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Nektar Therapeutics	Positive
Supernus Pharmaceuticals	Positive

75.9% of Nektar Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.63M	36.06	-$164.08M	-$8.42	N/A
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A

Nektar Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Supernus Pharmaceuticals beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Perrigo?

Perrigo (NYSE:PRGO) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

In the previous week, Perrigo had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 11 mentions for Perrigo and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Perrigo's score of -0.20 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A

95.9% of Perrigo shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 76.11%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 39.98%. Given Perrigo's higher probable upside, equities research analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Perrigo has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Supernus Pharmaceuticals beats Perrigo on 11 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A
Pacira BioSciences	$726.41M	1.25	$7.03M	$0.12	191.58

Supernus Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

In the previous week, Pacira BioSciences had 6 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Pacira BioSciences and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Pacira BioSciences' score of 0.75 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Pacira BioSciences shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Pacira BioSciences	0.70%	10.24%	5.47%

Supernus Pharmaceuticals presently has a consensus price target of $62.17, indicating a potential upside of 39.98%. Pacira BioSciences has a consensus price target of $29.40, indicating a potential upside of 27.88%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Omeros?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Omeros (NASDAQ:OMER) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Omeros had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Omeros and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Omeros' score of 0.31 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Supernus Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Omeros has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Omeros	N/A	-102.16%	64.87%

Supernus Pharmaceuticals currently has a consensus price target of $62.17, indicating a potential upside of 39.98%. Omeros has a consensus price target of $40.33, indicating a potential upside of 362.01%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

48.8% of Omeros shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Omeros has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.59	-$38.55M	-$0.51	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	12.47

Summary

Omeros beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.58B	$5.88B	$6.52B	$12.05B
Dividend Yield	N/A	0.69%	2.67%	5.66%
P/E Ratio	-87.08	8.72	24.00	24.42
Price / Sales	3.59	21.19	515.84	118.72
Price / Cash	11.76	8.43	27.48	37.92
Price / Book	2.40	4.07	10.60	6.82
Net Income	-$38.55M	$99.67M	$3.57B	$337.56M
7 Day Performance	-0.16%	-0.15%	0.59%	1.16%
1 Month Performance	-10.16%	2.58%	1.54%	3.16%
1 Year Performance	38.65%	116.73%	25.41%	30.60%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	3.4241 of 5 stars	$44.41 flat	$62.17 +40.0%	+38.7%	$2.58B	$718.95M	N/A	580	Gap Up
CORT Corcept Therapeutics	3.8467 of 5 stars	$75.36 +2.8%	$88.83 +17.9%	+18.3%	$8.07B	$761.41M	214.84	300	Positive News
NKTR Nektar Therapeutics	2.6575 of 5 stars	$56.11 -0.9%	$149.63 +166.7%	+591.3%	$1.89B	$55.63M	N/A	220
PRGO Perrigo	3.7699 of 5 stars	$11.14 -4.1%	$19.33 +73.6%	-58.8%	$1.54B	$4.25B	N/A	8,100	News Coverage
PCRX Pacira BioSciences	4.0702 of 5 stars	$23.36 +2.2%	$29.40 +25.8%	-5.2%	$920.00M	$726.41M	194.85	720	Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Perrigo?

Summary

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Summary

How does Supernus Pharmaceuticals compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Is CORT or SUPN more profitable?

Do insiders & institutionals have more ownership in CORT or SUPN?

Does the media favor CORT or SUPN?

Which has higher earnings & valuation, CORT or SUPN?

Do analysts rate CORT or SUPN?

Which has more risk & volatility, CORT or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Do analysts recommend NKTR or SUPN?

Is NKTR or SUPN more profitable?

Does the media prefer NKTR or SUPN?

Do insiders and institutionals believe in NKTR or SUPN?

Which has higher valuation & earnings, NKTR or SUPN?

Which has more risk and volatility, NKTR or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Perrigo?

Is PRGO or SUPN more profitable?

Does the media prefer PRGO or SUPN?

Which has preferable earnings and valuation, PRGO or SUPN?

Do institutionals & insiders believe in PRGO or SUPN?

Do analysts recommend PRGO or SUPN?

Which has more volatility and risk, PRGO or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Which has preferable earnings & valuation, SUPN or PCRX?

Which has more volatility and risk, SUPN or PCRX?

Does the media refer more to SUPN or PCRX?

Do institutionals and insiders believe in SUPN or PCRX?

Is SUPN or PCRX more profitable?

Do analysts prefer SUPN or PCRX?

Summary

How does Supernus Pharmaceuticals compare to Omeros?

Does the media refer more to SUPN or OMER?

Which has more risk and volatility, SUPN or OMER?

Is SUPN or OMER more profitable?

Do analysts rate SUPN or OMER?

Do institutionals and insiders believe in SUPN or OMER?

Which has preferable earnings and valuation, SUPN or OMER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools